Stattic

For research use only. Not for use in humans.

目录号：S7024

CAS No. 19983-44-9

Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 730.64	现货
25mg	RMB 901.23	现货
50mg	RMB 1392.12	现货
100mg	RMB 2375.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Stattic发表文献169篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Metab, 2020, 31(2):327-338

PubMed: 31928884 ( click the link to review the publication )

Nat Med, 2018, 24(5):563-571

PubMed: 29713085 ( click the link to review the publication )

Cell, 2017, 7;170(6):1134-1148.e10.

PubMed: 28886382 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4566

PubMed: 34315881 ( click the link to review the publication )

J Cell Biol, 2021, 220(9)e202004114

PubMed: 34287648 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01768-8

PubMed: 33824475 ( click the link to review the publication )

Cancer Lett, 2021, 519:328-342

PubMed: 34348188 ( click the link to review the publication )

Cancer Lett, 2021, 513:36-49

PubMed: 33991616 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5756

PubMed: 34228359 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):35

PubMed: 33736709 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):713

PubMed: 34272360 ( click the link to review the publication )

Front Immunol, 2021, 12:630196

PubMed: 33897686 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:631163

PubMed: 33937232 ( click the link to review the publication )

J Neuroinflammation, 2021, 18(1):182

PubMed: 34419081 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(3):3443-3458

PubMed: 33428604 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Transl Psychiatry, 2021, 11(1):298

PubMed: 34016951 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 208:111693

PubMed: 33396024 ( click the link to review the publication )

Biochem Pharmacol, 2021, 192:114688

PubMed: 34274354 ( click the link to review the publication )

Genes Brain Behav, 2021, e12729

PubMed: 33641239 ( click the link to review the publication )

Cell Signal, 2021, 87:110141

PubMed: 34487815 ( click the link to review the publication )

Phytother Res, 2021, 10.1002/ptr.7117

PubMed: 34038010 ( click the link to review the publication )

Prostate, 2021, 81(8):452-462

PubMed: 33822400 ( click the link to review the publication )
Exp Cell Res, 2021, 408(1):112856

PubMed: 34597680 ( click the link to review the publication )

Gastroenterol Rep (Oxf), 2021, 9(1):59-70

PubMed: 33747527 ( click the link to review the publication )

Blood Adv, 2021, 5(14):2863-2878

PubMed: 34297045 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-611538/v1

PubMed: None ( click the link to review the publication )

PLoS Pathog, 2021, 17(2):e1009303

PubMed: 33529218 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

Elife, 2020, 30;9. pii: e51317

PubMed: 32223889 ( click the link to review the publication )

J Hematol Oncol, 2020, 5;13(1):68

PubMed: 32503584 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32150944 ( click the link to review the publication )

Cell Death Discov, 2020, 2;6:42

PubMed: 32528731 ( click the link to review the publication )

J Mol Cell Biol, 2020, 1 pii: mjaa011

PubMed: 32236560 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):505

PubMed: 33246502 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Oxid Med Cell Longev, 2020,

PubMed: 32855767 ( click the link to review the publication )

J Am Heart Assoc, 2020, 9(18):e017071

PubMed: 32865099 ( click the link to review the publication )

Front Oncol, 2020, 5;10:652

PubMed: 32432040 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15563

PubMed: 32618105 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30632-8

PubMed: 33359364 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 69(1):115-126

PubMed: 31802182 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )

Cell Mol Neurobiol, 2020, 18

PubMed: 32424774 ( click the link to review the publication )
Invest New Drugs, 2020, 20

PubMed: 32436058 ( click the link to review the publication )

Life Sci, 2020, 242:117221

PubMed: 31881224 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

PLoS One, 2020, 15(11):e0242337

PubMed: 33180876 ( click the link to review the publication )

Int J Oral Sci, 2020, 12(1):38

PubMed: 33380723 ( click the link to review the publication )

Hum Exp Toxicol, 2020, 39(2):224-234

PubMed: 31610697 ( click the link to review the publication )

Exp Clin Endocrinol Diabetes, 2020, 10.1055/a-0998-7985

PubMed: 31896157 ( click the link to review the publication )

Pharmacol Res, 2020, 153:104661

PubMed: 31982491 ( click the link to review the publication )

J Cell Physiol, 2020, 235(2):1076-1089

PubMed: 31276203 ( click the link to review the publication )

Cell Signal, 2020, 65:109413

PubMed: 31494257 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):116-125

PubMed: 32123861 ( click the link to review the publication )

Front Immunol, 2020, 11:2031

PubMed: 33042115 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, S2352-345X(20)30190-9

PubMed: 33238220 ( click the link to review the publication )

Oncotarget, 2020, 11(33):3129-3143

PubMed: 32913557 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106143

PubMed: 32062080 ( click the link to review the publication )

Cell Death Dis, 2020, 11(7):531

PubMed: 32661236 ( click the link to review the publication )

Nat Commun, 2019, 10(1):716

PubMed: 30755611 ( click the link to review the publication )

Biomaterials, 2019, 219:119371

PubMed: 31352310 ( click the link to review the publication )

Mol Cancer, 2019, 18(1):40

PubMed: 30866952 ( click the link to review the publication )

Diabetes, 2019, 68(6):1303-1314

PubMed: 30936144 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Redox Biol, 2019, 20:451-457

PubMed: 30439686 ( click the link to review the publication )

Brain Behav Immun, 2019, 81:228-246

PubMed: 31207335 ( click the link to review the publication )
J Pathol, 2019, 248(4):438-451

PubMed: 30900255 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

EBioMedicine, 2019, 39:132-144

PubMed: 30528455 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1939

PubMed: 31817171 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846806

PubMed: 31205504 ( click the link to review the publication )

Cell Biol Toxicol, 2019, 10.1007/s10565-019-09471-x

PubMed: 30941654 ( click the link to review the publication )

Kidney Blood Press Res, 2019, 44(6):1453-1464

PubMed: 31722339 ( click the link to review the publication )

Oncogenesis, 2019, 8(8):39

PubMed: 31311917 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31019895 ( click the link to review the publication )

J Virol, 2019, 93(9)

PubMed: 30787154 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31575039 ( click the link to review the publication )

J Clin Periodontol, 2019, 10.1111/jcpe.13166

PubMed: 31286538 ( click the link to review the publication )

Respir Res, 2019, 20(1):184

PubMed: 31416461 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:1309-1319

PubMed: 30804683 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 380:114698

PubMed: 31394157 ( click the link to review the publication )

Cytokine, 2019, 119:81-89

PubMed: 30903867 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5315-5325

PubMed: 30320916 ( click the link to review the publication )

Neuroscience, 2019, 416:198-206

PubMed: 31374230 ( click the link to review the publication )

Int J Oncol, 2019, 10.3892/ijo.2019.4880

PubMed: 31545422 ( click the link to review the publication )

Cancer Med, 2019, 8(17):7345-7358

PubMed: 31631559 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

Oncol Rep, 2019, 41(1):437-446

PubMed: 30365081 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:1137-1146

PubMed: 30809095 ( click the link to review the publication )

Scand J Immunol, 2019, 89(6):e12761

PubMed: 30977163 ( click the link to review the publication )
Evid Based Complement Alternat Med, 2019, 2019:3909468

PubMed: 31485245 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3803-3808

PubMed: 31262907 ( click the link to review the publication )

Pathol Res Pract, 2019, 215(6):152392

PubMed: 30922625 ( click the link to review the publication )

Am J Nucl Med Mol Imaging, 2019,

PubMed: 31976162 ( click the link to review the publication )

Immunity, 2018, 48(4):787-798

PubMed: 29653697 ( click the link to review the publication )

Circulation, 2018, 30;138(18):2021-2035

PubMed: 29967195 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6236-6247

PubMed: 30131384 ( click the link to review the publication )

Blood Cancer J, 2018, 8(2):20

PubMed: 29440639 ( click the link to review the publication )

Cancer Lett, 2018, 436:52-62

PubMed: 30118844 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):375

PubMed: 29515107 ( click the link to review the publication )

Front Immunol, 2018,

PubMed: 29867938 ( click the link to review the publication )

Front Immunol, 2018, 9:1263

PubMed: 29930553 ( click the link to review the publication )

Mol Oncol, 2018, 12(7):1203-1215

PubMed: 29791786 ( click the link to review the publication )

Carcinogenesis, 2018, 39(9):1165-1175

PubMed: 29893810 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(3):489-501

PubMed: 29637003 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(11):1057-1064

PubMed: 30277836 ( click the link to review the publication )

Cell Cycle, 2018, 17(4):428-438

PubMed: 29468929 ( click the link to review the publication )

Int Immunopharmacol, 2018, 58:136-144

PubMed: 29587202 ( click the link to review the publication )

Transl Oncol, 2018, 11(2):487-497

PubMed: 29494948 ( click the link to review the publication )

Int J Mol Med, 2018, 42(1):497-504

PubMed: 29620257 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2018, 22(19):6308-6314

PubMed: 30338828 ( click the link to review the publication )

Scand J Immunol, 2018, 88(3):e12703

PubMed: 30047999 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):370-380

PubMed: 29471502 ( click the link to review the publication )
Tumour Biol, 2018, 40(1):1010428317731369

PubMed: 29320977 ( click the link to review the publication )

Prostaglandins Other Lipid Mediat, 2018, 138:31-40

PubMed: 30110652 ( click the link to review the publication )

Circ Res, 2017, 121(6):617-627

PubMed: 28743805 ( click the link to review the publication )

Oncogene, 2017, 36(48):6725-6737

PubMed: 28783177 ( click the link to review the publication )

Mol Ther Oncolytics, 2017, 6:90-99

PubMed: 28875159 ( click the link to review the publication )

Cell Death Dis, 2017, 8(4):e2725

PubMed: 28383559 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

J Mol Med (Berl), 2017, 95(2):221-233

PubMed: 27709266 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(3):433-447

PubMed: 28401002 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

Sci Rep, 2017, 7(1):11540

PubMed: 28912535 ( click the link to review the publication )

Am J Pathol, 2017, 187(5):980-986

PubMed: 28284718 ( click the link to review the publication )

Cell Signal, 2017, 32:48-58

PubMed: 28093267 ( click the link to review the publication )

Toxicol In Vitro, 2017, 45(Pt 1):10-18

PubMed: 28739487 ( click the link to review the publication )

Int J Mol Med, 2017, 40(5):1549-1556

PubMed: 28949390 ( click the link to review the publication )

PLoS One, 2017, 12(6):e0178844

PubMed: 28636670 ( click the link to review the publication )

Gene, 2017, 627:114-122

PubMed: 28603075 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):9111-9119

PubMed: 28990062 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(7):7466-7474

PubMed: 31966590 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29100353 ( click the link to review the publication )

Sci Rep, 2017, 10.1038/srep41404

PubMed: 28112250 ( click the link to review the publication )

Oncotarget, 2017, 8(37):61876-61889

PubMed: 28977911 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31227-31237

PubMed: 28415722 ( click the link to review the publication )
Leukemia, 2016, 30(6):1311-9

PubMed: 26854024 ( click the link to review the publication )

Cell Rep, 2016, 15(3):460-470

PubMed: 27068459 ( click the link to review the publication )

EBioMedicine, 2016, 8:132-149

PubMed: 27428425 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2294

PubMed: 27415424 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(7 Pt A):1579-88

PubMed: 27066979 ( click the link to review the publication )

Int J Cardiol, 2016, 210:85-92

PubMed: 26930642 ( click the link to review the publication )

Cancer Prev Res (Phila), 2016, 9(8):657-63

PubMed: 27267892 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2010-2023

PubMed: 26663388 ( click the link to review the publication )

Int J Oncol, 2016, 48(1):161-72

PubMed: 26549725 ( click the link to review the publication )

J Physiol Sci, 2016, 66(3):229-39

PubMed: 26541157 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Antioxid Redox Signal, 2015, 24(2):70-83

PubMed: 26154696 ( click the link to review the publication )

Neoplasia, 2015, 17(7):586-97

PubMed: 26297436 ( click the link to review the publication )

Transl Res, 2015, 166(4):384-98

PubMed: 25843671 ( click the link to review the publication )

Hum Pathol, 2015, 46(2):284-94

PubMed: 25537973 ( click the link to review the publication )

FEBS Lett, 2015, 589(1):52-8

PubMed: 25436422 ( click the link to review the publication )

FEBS Lett, 2015, 589(1):52-8

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0128406

PubMed: 26010889 ( click the link to review the publication )

J Interferon Cytokine Res, 2015, 10.1089/jir.2014.0128

PubMed: 25919795 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43992-4004

PubMed: 26556857 ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3681-y

PubMed: 26124007 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8244-54

PubMed: 25749519 ( click the link to review the publication )

J Exp Med, 2015, 212(12):2147-63

PubMed: 26552708 ( click the link to review the publication )

Tumour Biol, 2015, 36(12):9475-86

PubMed: 26124007 ( click the link to review the publication )
J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述

Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。

特性

Stattic是第一个非肽类小分子，抑制STAT3 SH2结构域的功能，无论在体外STAT3磷酸化状态。

靶点

STAT3 ^[1]
(Cell-free assay)

5.1 μM

体外研究

Stattic抑制gp130受体衍生的含磷酸化酪氨酸的肽结合到STAT3 SH2结构域，这种作用存在强烈的温度依赖性。Stattic对酪氨酸磷酸化的肽结合到酪氨酸激酶Lck的SH2结构域只有很微弱的作用效果。Stattic不抑制其他两个二聚体转录因子(c-Myc/Max 和 Jun/Jun)的二聚化。Stattic抑制荧光素标记的磷酸化肽段结合到STAT1和STAT5b的SH2域。Stattic浓度为10 μM，选择性抑制DNA与STAT3二聚体结合。Stattic抑制STAT3在Tyr705位点磷酸化，而对STAT1在Tyr701(HepG2细胞)位点磷酸化或 JAK1, JAK2, 和c-Src(MDA-MB-231和MDA-MB-235S细胞)磷酸化几乎没有抑制效果。Stattic增加STAT3依赖性的乳腺癌细胞系的凋亡率。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
H9c2	MljzSpVv[3Srb36gRZN{[Xl?	MkLnNVDjiIoQvF2=	NWixPWxqPOLCiXi=		NFTSfY1z\X[ncoPld{B1cGViZX\m[YN1eyCxZjDJUE0zPw>?	NH7IbFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzPVY{Oyd-Mk[zN\|k3OzN:L3G+
NPC	Mmi2SpVv[3Srb36gRZN{[Xl?	MnfBNE04NjViwsXN			MnPDZYJwdGm\|aHXzJGVOXC2uaXvlJI1wdGWldXzhdkBidHSncnH0bY9veyxiYX7kJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvckBqdmS3Y3XkJIJ6KFKNSWCgb45w[2umb4fu	NFTSNFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOVQ{OCd-MkW5NVU1OzB:L3G+
HASMC	NXfYUHNTTnWwY4Tpc44hSXO\|YYm=	MYCxMlI2NTVizszN	MljkNlAhdWmw	MVPEUXNQyqB?	M1rUSYlvcGmkaYTzJJAuMFlrLWPURXQuOSx\|LEWgd4lodmGuc9Mg	MkjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NEm2NlIoRjJ3OES5OlIzRC:jPh?=
H9c2	NHTDSmlHfW6ldHnvckBCe3OjeR?=	NWe3Rnd1Oi9zMDFOwG0>	NI\wSpYzKGh?	NF;PNnhFVVORwrC=	NY\USWh{[WK{b3fheIV{yqC2aHWgZ5l1d3C{b4TlZ5RqfmViZX\m[YN1eyCxZjDJUE0zPyCjZ3HpcpN1KFOK	MkLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MkC5NFcoRjJ3OEKwPVA4RC:jPh?=
A431	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1H5TlLDqM7:TR?=	MVuyxsBp		MnPPZoxw[2u\|IFXHSk1z\X[ncoPl[EBl\WO{ZXHz[ZMhcW5iY3XscEB3cWGkaXzpeJk>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{MESzOUc,OjV5MkC0N\|U9N2F-
A431	M1XCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXMdFMzyqEQvF2=	MmriNuKhcA>?		NHvMUJFqdmO{ZXHz[ZMhcW5iYYDvdJRwe2m\|IHnu[JVk\WRiYomgd4hqc2:waX6=	MorVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkC0N\|UoRjJ3N{KwOFM2RC:jPh?=
SiHa	NX;tc\|A1S2WubDDWbYFjcWyrdImgRZN{[Xl?	M3n0eFUuPzVibl2=	NHnZT5QzPMLiaNMg		NWG1cW5we2ixd4OgcY9zeGixbH;nfUBw\iCjIIT5dIlk[WxiYYDvdJRwfGmlIHPlcIwh[W6mIHTvd4Uu\GWyZX7k[Y51KGyxc4Ogc4Yh[2WubDD2bYFjcWyrdIpCpC=>	M3\GSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO5OlQ1Lz5{NUWzPVY1PDxxYU6=
SiHa	NUe1cXZCTnWwY4Tpc44hSXO\|YYm=	NVfsRVBNPS15NTDuUS=>	MkTFNlTDqGkEoB?=		M16wcpJm\HWlZYOgeIhmyqCyaH;zdIhwenmuYYTpc44h[XRidHjlJJR6em:\|aX7lJJJme2mmdXWgO\|A2yqB?	MkLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{m2OFQoRjJ3NUO5OlQ1RC:jPh?=
ECA109	M1m1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fT[lAuOjBizszN	MoS0NlTDqGkEoB?=		NIe1S3ZKSzVyPUWuOVAh\|ryP	NWfkc5RvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PVI1QDBpPkK1OFkzPDhyPD;hQi=>
TE13	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUGwMVIxKM7:TR?=	NHr0WJkzPMLiaNMg		MlHnTWM2OD14LkG1xsDPxE1?	MnzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK0PFAoRjJ3NEmyOFgxRC:jPh?=
KYSE150	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLWNE0zOCEQvF2=	MWOyOOKhcMLi		MV;JR\|UxRTF{Lk[0xsDPxE1?	NHjRWnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NlQ5OCd-MkW0PVI1QDB:L3G+
ECA109	MkPMR4xwdm:pZX7pZ{BUfXK4aY\hcEBCe3OjeR?=	MV[wMlXDqM7:TR?=	NVHx[5pDOjUEoHlCpC=>		MmHqd5VxeHKnc4Pld{B1cGViY3zvco9o\W6rYzDmc5Ju[XSrb36=	MnzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK0PFAoRjJ3NEmyOFgxRC:jPh?=
TE13	NU\abHRGS2yxbn;n[Y5q[yCVdYL2bZZidCCDc4PhfS=>	MXewMlXDqM7:TR?=	MUOyOOKhcMLi		NITYVHh{fXCycnXzd4V{KHSqZTDjcI9vd2enbnnjJIZwem2jdHnvci=>	MofkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK0PFAoRjJ3NEmyOFgxRC:jPh?=
KYSE150	Ml\xR4xwdm:pZX7pZ{BUfXK4aY\hcEBCe3OjeR?=	NFfYeIUxNjYEoN88US=>	NI\HS5EzPMLiaNMg		NY\wPHFve3WycILld5NmeyC2aHWgZ4xwdm:pZX7pZ{Bnd3KvYYTpc44>	MlKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK0PFAoRjJ3NEmyOFgxRC:jPh?=
ECA109	M{nybGZ2dmO2aX;uJGF{e2G7	MVGwMlXDqM7:TR?=	MVeyOOKhcMLi		NWK5fnhr\W6qYX7j[ZMhUVJvaX7keYNm\CCpZX7ldoF1cW:wIH;mJGRUSnN?	M2DQe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEmyOFgxLz5{NUS5NlQ5ODxxYU6=
PC3M-1E8	MV\GeY5kfGmxbjDBd5NigQ>?	NGPSbXUzNjVxNT:xNEDPxE1?	M1zVOVAuPCCq		M3WzcYlvcGmkaYTzJJRp\SCVVFHUN{Bi[3SrdnH0bY9vKGmwIHGg[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5mesLi	NWfUNZg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlE{PjVpPkK1NlYyOzZ3PD;hQi=>
PC3M-1E8	NUTzV41sTnWwY4Tpc44hSXO\|YYm=	MVGxNEDPxE1?	NVW5NHFmOjRiaB?=		NF;rRYpld3ewcnXneYxifGW\|IFLjcE15VCxic4Xyeol3cW5iYX7kJIMuVXml	MnHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkGzOlUoRjJ3Mk[xN\|Y2RC:jPh?=
PC3M-1E8	NEfiZZlHfW6ldHnvckBCe3OjeR?=	MUWxNEDPxE1?	Mn;lNlQhcA>?		MkPSbY5pcWKrdIOgTWwuPiCrbnT1Z4VlKFOWQWSzJIFkfGm4YYTpc44h[W6mIITo[UBKVC14LXnu[JVk\WRiU2TBWFMh[WO2aY\heIlwdg>?	NVOxSoV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlE{PjVpPkK1NlYyOzZ3PD;hQi=>
PC3M-1E8	M1ny[GNtd26xZ3XubYMhW3W{dnn2ZYwhSXO\|YYm=	M1zCXVIvPS93L{GwJO69VQ>?			MlrCbY5pcWKrdIRCpJRp\SClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bIm=	NFXMW3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2NVM3PSd-MkWyOlE{PjV:L3G+
MDA-MB-231	MXXGeY5kfGmxbjDBd5NigQ>?	MYOyNEDPxE1?	MmTINkBp		MoXj[ZhpcWKrdIOgV45icWxiYX7kJGUu[2GmaHXybY4h\XiycnXzd4lwdg>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3M{O0PUc,OjVzNUOzOFk9N2F-
H9c2	NWTtVVduTnWwY4Tpc44hSXO\|YYm=	M2HhcFIxKML3TR?=	M3vKcFMxKG2rbh?=	M1m5RWROW00EoB?=	NGX3WXNi[m:uaYPo[ZMheHKxcH;mc4wucW6mdXPl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IHLveIghe2W{NEezJIFv\CC2aIKzNFg>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNUC2O{c,OjVzMEWwOlc9N2F-
HaCaT	NE\1eoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjwW\|IyOCEEtV2=	NEPtZWMzOCCvaX6=	NE[zNnZFVVORwrC=	MkLa[Y5p[W6lZYOgd49z[W[nbnniMUBidmRic4XubZRqdmmkLXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25?	NWfJbYxiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVM6ODdpPkK1NFE{QTB5PD;hQi=>
Caki-1	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7zNVAhyrWP	NFrU[2QzOCCvaX6=	NVm0NXF2TE2VT9Mg	Mn7K[Y5p[W6lZYOgd49z[W[nbnniMUBidmRic4XubZRqdmmkLXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25?	M1jLXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEGzPVA4Lz5{NUCxN\|kxPzxxYU6=
HaCaT	M1\VTGFxd3C2b4Ppd{BCe3OjeR?=	MkmxNVAhyrWP	MnfzNlAhdWmw	MXfEUXNQyqB?	Ml;XbY5kemWjc3XzJJBzd3CxcoTpc45{KG:oIHHwc5B1d3SrYzDj[YxteyCmdXWgeI8hfHKnYYTt[Y51KHerdHigd49z[W[nbnniJI9zKHO3bnn0bY5q[g>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzM{mwO{c,OjVyMUO5NFc9N2F-
FHL-primed hNSCs	MmjtR4VtdCCYaXHibYxqfHliQYPzZZk>	NE\tbo0xNjB{LUWg{txO	MnXwO\|IhcA>?		NFLnfoht\WGmczD0c{B1cGVibH;zd{Bw\iClZXzsJJZq[WKrbHn0fUBifCCqaXfoJINwdmOnboTyZZRqd25?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NUSzOEc,OjR7NEW0N\|Q9N2F-
ELL-primed hNSCs	MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXrjNIRKOC5yMj21JO69VQ>?	MXm3NkBp		M2TUe4xm[WS\|IITvJJRp\SCub4PzJI9nKGOnbHygeoli[mmuaYT5JIF1KGirZ3igZ49v[2WwdILheIlwdg>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NUSzOEc,OjR7NEW0N\|Q9N2F-
SS	MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M3TWUVEuOTBizszN	NVPQTGFrPzJiaB?=	MmOzSG1UVw>?	Mor1Z4F2e2W\|IHGg[I9{\S2mZYDlcoRmdnRiaX7obYJqfGmxbjDv[kB1cGVidnnhZoltcXS7wrC=	M{T1XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W2NVEyLz5{NEe1OlEyOTxxYU6=
SeAx	MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MUmxMVExKM7:TR?=	M13qWVczKGh?	MoPxSG1UVw>?	NUTkSmNE[2G3c3XzJIEh\G:\|ZT3k[ZBmdmSnboSgbY5pcWKrdHnvckBw\iC2aHWgeoli[mmuaYT5xsA>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd3NkGxNUc,OjR5NU[xNVE9N2F-
HuT-78	NHK2[3ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NYmzR3BuOS1zMDFOwG0>	MkOxO\|IhcA>?	MWHEUXNQ	NVPMXFFG[2G3c3XzJIEh\G:\|ZT3k[ZBmdmSnboSgbY5pcWKrdHnvckBw\iC2aHWgeoli[mmuaYT5xsA>	Mnr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NU[xNVEoRjJ2N{W2NVEyRC:jPh?=
CD4+	NWTGfpFmSXCxcITvd4l{KEG\|c3H5	M3rKeFEx6oDLzszt	MWGyOEBp	NHHmc5NFVVOR	MkXvbY5lfWOnczDhdI9xfG:\|aYOgd5Rzd26pbIm=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd3NkGxNUc,OjR5NU[xNVE9N2F-
MCF-7	M1r6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXr5S2JKOC52NkmtN{44PSEQvF2=	Ml\ZOUBl		M2jBW5Jm\HWlZYOgZ4VtdCCwdX3i[ZIhe2mpbnnmbYNidnSueR?=	M3WyT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K4NFc5Lz5{NEeyPFA4QDxxYU6=
MCF-7/LCC1	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY[wMlQ3QS1\|Lke1JO69VQ>?	NHHGc4Y2KGR?		MkHjdoVlfWOnczDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7	NFHOV3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyPFA4QCd-MkS3NlgxPzh:L3G+
MCF-7/LCC9	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFT6XJExNjR4OT2zMlc2KM7:TR?=	M4jTbFUh\A>?		MmjrdoVlfWOnczDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{OEC3PEc,OjR5MkiwO\|g9N2F-
HaCaT	M2\KcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXKxNEDDvU1?	NVmweVcxOjBibXnu	NVPHbHJpTE2VT9Mg	Mknz[Y5p[W6lZYOg[ZZmem:uaX31d{1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25?	M{LVT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzNVMyLz5{NESyN\|E{OTxxYU6=
HaCaT	NGLCU5NCeG:ydH;zbZMhSXO\|YYm=	NX;lN\|VjOTBiwsXN	M3LF[\|IxKG2rbh?=	NVXWfmI2TE2VT9Mg	NYjMXFZo\W6qYX7j[ZMhfGinIHHwc5B1d3SrYzDl[oZm[3S\|IH;mJIV3\XKxbHnteZM>	M37BS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzNVMyLz5{NESyN\|E{OTxxYU6=
MDA-MB-231	NYTsb41iTnWwY4Tpc44hSXO\|YYm=	MYGxNEDDvU1?	NWP5S5NIOjRiaB?=	M{Hyb2ROW00EoB?=	NEXsUmpz\WS3Y3XzJHAuW1SDVEOg[ZhxemW\|c3nvci=>	MmPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|N{[1PFYoRjJ2M{e2OVg3RC:jPh?=
SUM-159	M4LVPWZ2dmO2aX;uJGF{e2G7	MmfENVAhyrWP	NITxV5UzPCCq	MoHlSG1UV8Li	NH;GNWFz\WS3Y3XzJHAuW1SDVEOg[ZhxemW\|c3nvci=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN5NkW4Okc,OjR\|N{[1PFY9N2F-
SK-BR-3	M1LkVWZ2dmO2aX;uJGF{e2G7	NELBcGsyOCEEtV2=	NVLke4NPOjRiaB?=	M1rjbGROW00EoB?=	M4n6bZJm\HWlZYOgVE1UXEGWMzDlfJBz\XO\|aX;u	NV\XN\|hMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO\|Y2QDZpPkK0N\|c3PTh4PD;hQi=>
MCF7-HER2	M3rBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTwTYhrOC1zMDFOwG0>	NYP6SJlzPDhiaB?=	Moe0SG1UVw>?	NUHafG1ucW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk>	NFOwTlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O\|UxQCd-MkSyPVc2ODh:L3G+
MCF7-HER2	NFjISYpHfW6ldHnvckBCe3OjeR?=	NVjMWJdlPSEQvF2=	NF2wWlczPCCq	M2rxSmROW09?	MkXF[IlucW6rc3jld{BUd3hvMjygU4N1NTRuIHHu[EB{dHWpIHX4dJJme3Orb36=	NFnae409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O\|UxQCd-MkSyPVc2ODh:L3G+
MCF7-HER2	M3iyb2Z2dmO2aX;uJGF{e2G7	M1H1NlUh\|ryP	Ml\CNlQhcA>?	NH;mZVZFVVOR	NGSxdYZl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wy\|IH;mJGVOXCCvYYLr[ZJ{NCC4aX3lcpRqdiCjbnSgd4x2\w>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7N{WwPEc,OjR{OUe1NFg9N2F-
MCF7-HER2	M2jjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnoS5NNPSEQvF2=	MW[yOEBp	NFXvcZhFVVOR	NFfHPFRmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHPvcYJqdmWmIIfpeIghUGW{Y3XweIlv	M3LNRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OVA5Lz5{NEK5O\|UxQDxxYU6=
HMECs	MnS0SpVv[3Srb36gRZN{[Xl?	NVi3[29LOTBizszN	NGSycnozKGh?		NYCxfXhPcW6qaXLpeJMhUU[QzsJCpI1m\GmjdHXkJJBpd3OyaH;yfYxifGmxbjDv[kBUXEGWMTygV3RCXDJiYX7kJHNVSVR\|	NYPWN4ZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVE{OjdpPkK0NlEyOzJ5PD;hQi=>
HTR8/SVneo	MkTmSpVv[3Srb36gRZN{[Xl?	MVqxxsDPxE4EoB?=	M3;LTFHDqGh?		NFfnW5h{fXCycnXzd4VlKE:VTT3pcoR2[2WmIGPURXQ{KHCqb4PwbI9zgWyjdHnvci=>	NG\oSWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2NFI1OSd-MkSwOlAzPDF:L3G+
HTR8/SVneo	NF\0bGtHfW6ldHnvckBCe3OjeR?=	NFjBWVMxNjVxMdMg{txOyqB?	NHPyOVM1QCCq		MnfsdoV{fG:{ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckB{fXCycnXzd4VlKGK7IF;TUS=>	NFz6UYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2NFI1OSd-MkSwOlAzPDF:L3G+
HTR8/SVneo	M{PmXGZ2dmO2aX;uJGF{e2G7	M{Dw[FHDqM7:TdMg	MVm0PEBp		M1;vWpNq\26rZnnjZY51dHliaX7jdoVie2W\|IH3p[5JifGmxbjDifUBQW04EoB?=	NFnN[nE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2NFI1OSd-MkSwOlAzPDF:L3G+
C13*	M1TjNGFxd3C2b4Ppd{BCe3OjeR?=	NF7ZR4YxNTFyIN88US=>	MX[yOE81QCCq		M1SzfIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4MkW1PEc,OjN7NkK1OVg9N2F-
OV2008	NXrsR3g5SXCxcITvd4l{KEG\|c3H5	M1HqXVAuOTBizszN	M4W2SFI1NzR6IHi=		MoDHbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NVWzbnhNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlI2PThpPkKzPVYzPTV6PD;hQi=>
C13*	M2WyfmFxd3C2b4Ppd{BCe3OjeR?=		M1LtWFI1NzR6IHi=		NXzkN2hq\W6qYX7j[ZMh[2m\|cHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	MnLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkK1OVgoRjJ\|OU[yOVU5RC:jPh?=
OV2008	Mn;0RZBweHSxc3nzJGF{e2G7		NHqyNXYzPC92ODDo		MmLs[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4MkW1PEc,OjN7NkK1OVg9N2F-
W480	NFTLTppHfW6ldHnvckBCe3OjeR?=	M4n4cVIvPS9zMDFOwG0>	MnvJN\|AhdWmw	M3fufmROW09?	Ml\Id4Vve2m2aYrld{Bk\WyuczD0c{BkcGWvb4Lh[IlwfGincnHwfUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NYG4Z4tORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|Q6PzJpPkKzPVM1QTd{PD;hQi=>
SW837	NX:yN\|RCTnWwY4Tpc44hSXO\|YYm=	M3qwUlIvPS9zMDFOwG0>	M{Lnb\|MxKG2rbh?=	Mn\USG1UVw>?	NGXkPHp{\W6\|aYTpfoV{KGOnbHzzJJRwKGOqZX3vdoFlcW:2aHXyZZB6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MlPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7M{S5O\|IoRjJ\|OUO0PVczRC:jPh?=
T24	M1zXPWZ2dmO2aX;uJGF{e2G7	MnqyNk8yOC9{MDFOwG0>	M2f4[\|I1KGh?		MVLjZZV{\XNiZH;z[U1l\XCnbnTlcpQhcW6qaXLpeIlwdiCxZjD0bIUhS1iFTEGyMYlv\HWlZXSgbY5kemWjc3Wgc4YhcW64YXTpcoch[2WubIO=	Moj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Mk[wO\|koRjJ\|NUK2NFc6RC:jPh?=
CNE1	M2juNmZ2dmO2aX;uJGF{e2G7	MWSyNEDDvU1?	M3vYRlQ5KGh?		MlXSZoxw[2u\|IITo[UBKVC14IHnuZ5Jm[XOnZDDwbI9{eGixconsZZRqd25ib3[gV5RifDN?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE2	Ml7RSpVv[3Srb36gRZN{[Xl?	MUSyNEDDvU1?	MUm0PEBp		M{POUoJtd2OtczD0bIUhUUxvNjDpcoNz\WG\|ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHN1[XR\|	M2W2e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
HONE1	M{TOOWZ2dmO2aX;uJGF{e2G7	MViyNEDDvU1?	NIO5dlY1QCCq		M3KwUIJtd2OtczD0bIUhUUxvNjDpcoNz\WG\|ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHN1[XR\|	MkTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
CNE1	NUjZcG1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHmSVA1KM7:TR?=			Mkjrd4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHygeoli[mmuaYT5	M2rGblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE1	MkP1SpVv[3Srb36gRZN{[Xl?	MnnwNE0zOCEQvF2=	M13zZlAuPCCq		M{jxZ4lvcGmkaYTzJHN1[XR\|IHHjeIl3[XSrb36gbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	NFzSXWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O4NlkyPCd-MkOzPFI6OTR:L3G+
CNE2	MkTnSpVv[3Srb36gRZN{[Xl?	NXHZUJlGOC1{MDFOwG0>	NGDzU3ExNTRiaB?=		M2O3dIlvcGmkaYTzJHN1[XR\|IHHjeIl3[XSrb36gbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	MmL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
HONE1	MXXGeY5kfGmxbjDBd5NigQ>?	M1nRUFAuOjBizszN	NY\wSGhkOC12IHi=		NHznXVNqdmirYnn0d{BUfGG2MzDhZ5RqfmG2aX;uJIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE1	Mo\2R4VtdCCYaXHibYxqfHliQYPzZZk>	M3zoVVAvPS14NDFOwG0>	M4Xmd\|Q5KGh?		M33odZN2eHC{ZYPz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	NUDa[\|RnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
CNE2	NUW4PJNES2WubDDWbYFjcWyrdImgRZN{[Xl?	MYGwMlUuPjRizszN	NF;HeoE1QCCq		NU\RR3k6e3WycILld5NmeyClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	NUjLTYd[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
HONE1	MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NIraUGIxNjVvNkSg{txO	MlvlOFghcA>?		NHT6[Wt{fXCycnXzd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	M{\WVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
C666-1	MlLQR4VtdCCYaXHibYxqfHliQYPzZZk>	NEj2UVQxNjVvNkSg{txO	M3fyeFQ5KGh?		MmC0d5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	NUHLT3J4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
CNE1	NXzMNlFOSXCxcITvd4l{KEG\|c3H5	NHLUd48yOCEEtV5CpC=>	MkjtOFghcA>?		MofnbY5lfWOnczDhdI9xfG:\|aYRCpC=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE2	MWHBdI9xfG:\|aYOgRZN{[Xl?	NInQbYUyOCEEtV5CpC=>	NWixcJVtPDhiaB?=		NX;STnRYcW6mdXPld{BieG:ydH;zbZPDqA>?	MnWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
HONE1	MoTwRZBweHSxc3nzJGF{e2G7	MVWxNEDDvU4EoB?=	NXjDUJB6PDhiaB?=		NVTOO\|A4cW6mdXPld{BieG:ydH;zbZPDqA>?	M4ixPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE2	M2L1W2NmdGxiVnnhZoltcXS7IFHzd4F6	NH\mPIYyNzJizszN	MoewOFghcA>?		NVm3Oldje2Wwc3n0bZpmKGOnbHzzJJRwKHKjZHnveIhmemGyeR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
HONE1	M4foT2NmdGxiVnnhZoltcXS7IFHzd4F6	NE\6b5EyNzJizszN	MmjDOFghcA>?		M17RWpNmdnOrdHn6[UBk\WyuczD0c{Bz[WSrb4To[ZJieHl?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
C666-1	MlW4R4VtdCCYaXHibYxqfHliQYPzZZk>	MUKxM\|Ih\|ryP	MWO0PEBp		M3;LWJNmdnOrdHn6[UBk\WyuczD0c{Bz[WSrb4To[ZJieHl?	NUHiOYdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
HEC-1A	Ml7wSpVv[3Srb36gRZN{[Xl?	MmHRNeKh\|ryPwrC=	M3[zTVI1KGh?	NWLidIF4TE2VTx?=	M3LPWYJtd2OtczD0bIUhVVWFMkCt[Y5p[W6lZXSgbY53[XOrb36geJJq\2encnXkJIJ6KDFyJTDGRnM>	NGnOV4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2NlIxQCd-MkOyOlIzODh:L3G+
RL95-2	M4rQXmZ2dmO2aX;uJGF{e2G7	NX\pR4RzOcLizszNxsA>	M2\nRlI1KGh?	MVfEUXNQ	MnLaZoxw[2u\|IITo[UBOXUN{MD3lcohidmOnZDDpcpZie2mxbjD0dolo\2W{ZXSgZpkhOTBnIF\CVy=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4MkKwPEc,OjN{NkKyNFg9N2F-
HEC-1A	M3O5SWZ2dmO2aX;uJGF{e2G7	MYCxxsDPxE4EoB?=	MV6yOEBp	NG\aZ21FVVOR	MljnZoxw[2u\|IITo[UBOXUN{MD3lcohidmOnZDDpcpZie2mxbjD0dolo\2W{ZXSgZpkhTUeIwrC=	NUnIVpNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlIzODhpPkKzNlYzOjB6PD;hQi=>
RL95-2	NED1bHpHfW6ldHnvckBCe3OjeR?=	MYexxsDPxE4EoB?=	M{fTOVI1KGh?	NFHtPYRFVVOR	M3nDWoJtd2OtczD0bIUhVVWFMkCt[Y5p[W6lZXSgbY53[XOrb36geJJq\2encnXkJIJ6KEWJRtMg	NVPmVGptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlIzODhpPkKzNlYzOjB6PD;hQi=>
CT26	MlvySpVv[3Srb36gRZN{[Xl?	MVmyNEBuVQ>?	MWqxJIg>		MoLqd5VxeHKnc4Pld{BJT0ZvaX7keYNm\CCYRVfGJIV5eHKnc4Ppc47DqA>?	M4W0WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkOzNVY{Lz5{M{KzN\|E3OzxxYU6=
UM-SCC-17B	NELj[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXu4cGZ6UUN3ME2yMlU3OiEEsTCwMlQxQSEQvF2sJGdKPTB;MT6yO\|khyrFiMD6xPVQh\|ryP	NYHsTGc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3O\|A5QTlpPkKyO\|cxQDl7PD;hQi=>
OSC-19	MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLlNGZKSzVyPUOuOFgyKMLzIECuPVU{KM7:TTygS2k2OD1zLkO2OkDDuSByLke3NEDPxE1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEi5PUc,OjJ5N{C4PVk9N2F-
Cal33	NF;xVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDDTWM2OD1{LkK4NkDDuSByLkSyN{DPxE1uIFfJOVA:OS5\|NEmgxtEhOC5\|NkOg{txO	Ml:xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5N{C4PVkoRjJ{N{ewPFk6RC:jPh?=
UM-SCC-22B	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rrOWlEPTB;Mj62OFghyrFiMD61OFIh\|ryPLDDHTVUxRTFwM{KwJOKyKDBwMkC0JO69VQ>?	NGXRWZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFg6QSd-MkK3O\|A5QTl:L3G+
UM-SCC-17B	Mn\4SpVv[3Srb36gRZN{[Xl?	MUmwMVMxKM7:TR?=	M1PyU\|AuOjRiaB?=		NFn3PItqdmirYnn0d{BUXEGWMzDhZ5RqfmG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	M3uyNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
OSC-19	NUHpZmloTnWwY4Tpc44hSXO\|YYm=	NGHLTpgxNTNyIN88US=>	NYnNcZZZOC1{NDDo		NYm1d\|FscW6qaXLpeJMhW1SDVEOgZYN1cX[jdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5	NG\rVYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFg6QSd-MkK3O\|A5QTl:L3G+
Cal33	M1znbGZ2dmO2aX;uJGF{e2G7	Mny5NE0{OCEQvF2=	M17uNFAuOjRiaB?=		MVrpcohq[mm2czDTWGFVOyCjY4TpeoF1cW:wIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl?	M{HLWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
UM-SCC-22B	MXPGeY5kfGmxbjDBd5NigQ>?	Mon5NE0{OCEQvF2=	MYewMVI1KGh?		MXHpcohq[mm2czDTWGFVOyCjY4TpeoF1cW:wIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl?	NUO1O3NmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3O\|A5QTlpPkKyO\|cxQDl7PD;hQi=>
U-87MG	M{PtS2NmdGxiVnnhZoltcXS7IFHzd4F6	M17CNVAuOTBizszN	MWm3NkBp	NXj3[4c2TE2VTx?=	MYTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MnPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{[2PFIoRjJ3NEO2OlgzRC:jPh?=
U-373MG	M2\qRWNmdGxiVnnhZoltcXS7IFHzd4F6	M4jrPVAuOTBizszN	Mn;CO\|IhcA>?	M3u5WWROW09?	M3jDRYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	M3zMTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO2OlgzLz5{NUSzOlY5OjxxYU6=
SH-SY5Y	NF3Rc4tE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVT0dI0{OC1zMDFOwG0>	M4WyeFczKGh?	NUTnOJBxTE2VTx?=	M{POU4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|Nk[4Nkc,OjV2M{[2PFI9N2F-
Tu-9648	NV\odJk6S2WubDDWbYFjcWyrdImgRZN{[Xl?	MnvJNE0yOCEQvF2=	NWj3UXlNPzJiaB?=	M2\5emROW09?	MUnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	NUXLU\|FERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|Y3QDJpPkK1OFM3Pjh{PD;hQi=>
Neuro-2a	MkLrR4VtdCCYaXHibYxqfHliQYPzZZk>	NVvxdIdVOC1zMDFOwG0>	Mo\5O\|IhcA>?	NHPjNZRFVVOR	NIDMdm1qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	MmHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{[2PFIoRjJ3NEO2OlgzRC:jPh?=
PCNs	M4Xwb2NmdGxiVnnhZoltcXS7IFHzd4F6	M1[3bVAuOTBizszN	NFPTeJA4OiCq	NWTrdIhITE2VTx?=	NFP4eXVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M4T0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO2OlgzLz5{NUSzOlY5OjxxYU6=
PGCs	M3nlNGNmdGxiVnnhZoltcXS7IFHzd4F6	NXvnPGg1OC1zMDFOwG0>	M3jTc\|czKGh?	NInQPYhFVVOR	MnribY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MoT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{[2PFIoRjJ3NEO2OlgzRC:jPh?=
RAW264.7	NUexOmpGTnWwY4Tpc44hSXO\|YYm=	MXuxNEDPxE1?	M3zXZlEzKGh?		NH\xPZZi[nKxZ3H0[ZMhfGinIH3SUmEh\XiycnXzd4lwdnNib3[gTmFMOixiU2TBWFEtKFOWQWSyMEBidmRiU2TBWFMhcW6mdXPl[EBjgSCGT16gZY5lKFRvMjD0c5hqdg>?	M{HCSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEW0OFMyLz5{MkS1OFQ{OTxxYU6=
RAW264.7	NYT2cnI5SXCxcITvd4l{KEG\|c3H5	M3POTFUwOTBizszN	NVj5W2w5PDVibXnu		NEj2Z4JmdmijbnPld{B1d3irboOgbY5lfWOnZDDhdI9xfG:\|aYOgZY5lKE2PUDDsc5N{	NXy0dFg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OVQ1OzFpPkKyOFU1PDNzPD;hQi=>
SW480	M{i2bmNmdGxiVnnhZoltcXS7IFHzd4F6	MX61M\|ExNzJyIN88US=>	NGLYXlI4OiCq		NXjudFZWcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgc4YhfGinIFHMSGgsN0OGMUOzL:Kh[2WubIO=	MkHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MECzPVcoRjJzOUCwN\|k4RC:jPh?=
HCT116	NEDlXJpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NWfoUppNPS9zMD:yNEDPxE1?	NFXtUZM4OiCq		M2PlRYlvcGmkaYTzJINmdGxidnnhZoltcXS7IH;mJJRp\SCDTFTIL{9ETDF\|MzxCpINmdGy\|	M2DZdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUCwN\|k4Lz5{MUmwNFM6PzxxYU6=
DLD-1	MlnhR4VtdCCYaXHibYxqfHliQYPzZZk>	NUWxV4x5PS9zMD:yNEDPxE1?	MXS3NkBp		NHj4cJdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDv[kB1cGViQVzETEswS0RzM{OrxsBk\Wyucx?=	NFS4ZXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmwNFM6Pyd-MkG5NFA{QTd:L3G+
SNU387	MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXzNVZl[OjEEoN88UeKh	MVmyOEBp		NIqxOY5z\WS3Y3XzJINmdGxidnnhZoltcXS7	NWSxeJJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNVE6PzVpPkKxN\|EyQTd3PD;hQi=>
SNU398	Mkn4R4VtdCCYaXHibYxqfHliQYPzZZk>	MYGyNOKh\|ryPwrC=	M3jHT\|I1KGh?		MXjy[YR2[2W\|IHPlcIwhfmmjYnnsbZR6	NX;IbpBDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNVE6PzVpPkKxN\|EyQTd3PD;hQi=>
HepG2	M3LSXmNmdGxiVnnhZoltcXS7IFHzd4F6	MWiyNOKh\|ryPwrC=	MViyOEBp		NFvmfVNz\WS3Y3XzJINmdGxidnnhZoltcXS7	M3K2NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{GxPVc2Lz5{MUOxNVk4PTxxYU6=
Huh-7	Mle5R4VtdCCYaXHibYxqfHliQYPzZZk>	MY[yNOKh\|ryPwrC=	MnLLNlQhcA>?		NIDieIZz\WS3Y3XzJINmdGxidnnhZoltcXS7	M3TOXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{GxPVc2Lz5{MUOxNVk4PTxxYU6=
VSMC	NFjnbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTsN{82NzFyIN88US=>	MluwN\|AhdWmw	NXj1cFl2TE2VTx?=	MnrmdJJmfmWwdIOgVGRITi1iYX7kJJRpem:vYnnuMY1m\GmjdHXkJHZUVUNicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NGjiPHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi0O\|MxPid-MkC4OFc{ODZ:L3G+
MDA-MB-231	MYfBdI9xfG:\|aYOgRZN{[Xl?	MlrCNVAh\|ryP	Ml;CNlQhcA>?	MYfEUXNQyqB?	MkjzbY5lfWOnczDhdI9xfG:\|aYO=	M1;ZTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUG0NFA2Lz5zN{GxOFAxPTxxYU6=
MDA-MB-435S	NH\abGtCeG:ydH;zbZMhSXO\|YYm=	M4nreFExKM7:TR?=	MUmyOEBp	MXfEUXNQyqB?	MW\pcoR2[2W\|IHHwc5B1d3Orcx?=	NInLeXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GxOFAxPSd-MUexNVQxODV:L3G+
AsPC1	M2P5NmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHP6fIw4OiCqcoO=		NIr5VFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFHzVGMyKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCxMlMzKM7:TT6=	MnjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MES5OlYoRjJ2OUC0PVY3RC:jPh?=
MDA-MB-231	NYTFSGRSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4TxdFczKGi{cx?=		MmTsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDFVk1v\WejdHn2[UBidmRidILpdIxmNW6nZ3H0bZZmKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IEKuPFkh\|ryPLh?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNEm2Okc,OjR7MES5OlY9N2F-
MCF7	NH\ZbHZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUK3NkBpenN?		NWHYb3lTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBGWi2yb4PpeIl3\SCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUA{NjZizszNMi=>	NX;ZZ5VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFQ6PjZpPkK0PVA1QTZ4PD;hQi=>
PANC1	MlvRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIXPfYo4OiCqcoO=		MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCDTlOxJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB\|Lke3JO69VS5?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNEm2Okc,OjR7MES5OlY9N2F-
MDA-MB-231	M3K2SGN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mn7NOFghcHK\|		M33IcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEvPTZizszNMi=>	NWPK[mtwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDlpPkK2N\|k3Pjh7PD;hQi=>
MDA-MB-435S	M{jHXWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoW0OFghcHK\|		M33EUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N\|VUKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyNjh5IN88UU4>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7Nk[4PUc,OjZ\|OU[2PFk9N2F-
MCF7	NHr1WoFEgXSxdH;4bYNqfHliYYPzZZk>		MkfwOFghcHK\|		NG\yfXJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{LkG2JO69VS5?	NVOyTlc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDlpPkK2N\|k3Pjh7PD;hQi=>
A549	MWHDfZRwfG:6aXPpeJkh[XO\|YYm=		NX7FcYdNPDhiaILz		MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjVizszNMi=>	NEPqWVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
DU145	NUHGNVVSS3m2b4TvfIlkcXS7IHHzd4F6		M3LXeVQ5KGi{cx?=		NHW4fJdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj61JO69VS5?	MmTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OU[2PFkoRjJ4M{m2Olg6RC:jPh?=
PANC1	M2fISWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MXe0PEBpenN?		NF\PTWxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSU6FMTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj65JO69VS5?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7Nk[4PUc,OjZ\|OU[2PFk9N2F-
HCT116	NGH6eYVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MoDlO\|IhcHK\|		M1fOdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlA5KM7:TT6=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzdzOES3NEc,Ojd5MUi0O\|A9N2F-
MDA-MB-231	MlS2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Moq0O\|IhcHK\|		MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEvPjhizszNMi=>	MoXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUi0O\|AoRjJ5N{G4OFcxRC:jPh?=
MCF7	NFK4RYNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYO3NkBpenN?		NF23O5VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuN\|Yh\|ryPLh?=	NEnkT4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{exPFQ4OCd-Mke3NVg1PzB:L3G+
A549	MnPQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MlXnO\|IhcHK\|		NXXGO41jSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0MlQh\|ryPLh?=	NGDQUIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{exPFQ4OCd-Mke3NVg1PzB:L3G+
AD293	MUHGeY5kfGmxbjDhd5NigQ>?		M2Xi[FYhcHK\|		MnLiTY5pcWKrdHnvckBw\iCLRl7nZY1u[S2\|dHnteYxifGWmIFfGVE9HVEGJLYTh[4dm\CCVVFHUN{BlcW2ncnn6ZZRqd25iaX6gbJVu[W5iQVSyPVMh[2WubIOgbY5kfWKjdHXkJIZweiB4IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOsJGlEPTBiPTC1MlEh\|ryPLh?=	M3PvRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkK4NFAxLz5\|MEKyPFAxODxxYU6=
MDA-MB-231	MYLGeY5kfGmxbjDhd5NigQ>?	MmL2NUB1dyBzMDD1US=>	M2i1UVEzKGi{cx?=		NYLYZZY3UW6qaXLpeIlwdiCxZjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiVInyO\|A2KGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiMTD0c{AyOCC3TTDh[pRmeiBzMjDodpMh[nlid3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MojoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MES5OlYoRjJ2OUC0PVY3RC:jPh?=
MDA-MB-231	MWjBcpRq[2GwY3XyJIF{e2G7	NGrZdIYyKHSxIEGwJJVO	NYDjNmlNPDhiaILz		MYnBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vNCCjcH;weI9{cXNiYX7kJINmdGy3bHHyJI1wenCqb3zv[4lk[WxiY3jhcodmeyCjdDCxJJRwKDFyIIXNJIFnfGW{IES4JIhzeyCkeTDsbYdpfCCvaXPyc5Nkd3C7	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNEm2Okc,OjR7MES5OlY9N2F-
MDA-MB-231	NU[yeYpkTnWwY4Tpc44h[XO\|YYm=	M{PHVlEhfG9iMUCgeW0>	NWLxb\|htOTJiaILz		Mo\TSIVkemWjc3WgbY4hW1SDVEOgdJJwfGWrbjDlfJBz\XO\|aX;uJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOSC2bzCxNEB2VSCjZoTldkAyOiCqcoOgZpkhf2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NVXkZY1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFQ6PjZpPkK0PVA1QTZ4PD;hQi=>
MCF7	M1ixNGZ2dmO2aX;uJIF{e2G7		MXGxNkBpenN?		NILlNWZKdmirYnn0bY9vKG:oIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCC\N{C1JIlvKGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgNVIhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	MlL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OU[2PFkoRjJ4M{m2Olg6RC:jPh?=
MDA-MB-435S	M4LKbmZ2dmO2aX;uJIF{e2G7		NVL6[2NQOTJiaILz		NV\pUJVUUW6qaXLpeIlwdiCxZjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiWUewOUBqdiCqdX3hckBOTEFvTVKtOFM2WyClZXzsd{Bi\nSncjCxNkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NXjRVmV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDlpPkK2N\|k3Pjh7PD;hQi=>
MDA-MB-231	MV3GeY5kfGmxbjDhd5NigQ>?		NUiwflc1OTJiaILz		Mmi4TY5pcWKrdHnvckBw\iCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhYTdyNTDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHmeIVzKDF{IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	Ml;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OU[2PFkoRjJ4M{m2Olg6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT3 / STAT3 ; PubMed: 25261365 Oncotarget (A) PC3M-1E8 cells were treated with different doses of Stattic for 4 h. (B) PC3M-1E8 cells were treated with 10 μM Stattic for different time points. Survivin / c-Myc / Bcl-xl ; PubMed: 25261365 Oncotarget Western blot analysis of STAT3 downstream targets in PC3M-1E8 cells treated with 10 μM Stattic for 24 h. PARP / C-PARP / Caspase-3 / C-Caspse-3 ; PubMed: 23382914 PLoS One NPC cells were exposed to the indicated concentrations of Stattic for 48 h; apoptotic cells were measured by western blot analysis of cleaved PARP and cleaved caspase-3. Protein levels were quantified using ImageJ software.	25261365 23382914
Immunofluorescence	p-STAT3 / STAT3 / Survivin ; PubMed: 25261365 Oncotarget Cellular localization of pSTAT3 and survivin (green) was observed by confocal microscopy after immunofluorescent staining of PC3M-1E8 cancer cells treated with 10 μM Stattic.	25261365
Growth inhibition assay	Cell viability; PubMed: 23382914 PLoS One Stattic inhibits the cell viability of NPC cells in a time-dependent manner. CNE2 cells were treated with 8 µM Stattic for the indicated times, and cell viability was measured by the MTT assay.	23382914
ELISA	BDNF; PubMed: 27456333 Sci Rep BDNF secretion was analyzed using ELISA in A549 and H1299 cells treated with or without Stattic. Results are shown as the mean ± S.E. n = 3; *p < 0.05, vs Control group, Student’s t-test.	27456333

激酶实验： ^[1]	- 合并高通量筛选和荧光偏振检测: 在约30°C下进行筛选。通过实验化合物与STAT1, STAT5, 和 Lck 的SH2结构域结合的类似实验验证筛选的特异性。所有FP实验的Buffer组分的终浓度为10 mM HEPES(pH 7.5),1 mM EDTA,0.1% Nonidet P-40,50 mM NaCl,和10% DMSO。二硫苏糖醇的存在对抑制活性是必不可少的。肽序列为:STAT3,5-carboxyfluorescein-GY(PO₃H₂)LPQTV-NH2; STAT1, 5-carboxyfluorescein-GY(PO₃H₂)DKPHVL;STAT5, 5-carboxyfluorescein-GY(PO₃H₂)LVLDKW; 和 Lck, 5-carboxyfluorescein-GY(PO₃H₂)EEIP。在 30°C下进行特异性分析, 使用150 nM蛋白(STAT1,STAT3,和STAT5)。在37°C下进行分析，使用370 nM 蛋白(STAT3)或100 nM蛋白 (Lck)。蛋白与实验化合物在Eppendorf管中在指定温度环境下温育60分钟，然后加入相应的5-carboxyfluorescein标记的肽（终浓度为10 nM）。混合物至少平衡30分钟，然后在室温下测量。实验化合物在20×stock在DMSO中稀释到指定浓度。使用 SigmaPlot绘制结合曲线和抑制曲线。独立实验中，所有竞争曲线都需重复三次。
细胞实验： ^[2]	- 合并 Cell lines: Ly3细胞 Concentrations: ~2.5 μM Incubation Time: 48小时 Method: MTS (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: Ly3亲本NOD/SCID IL2R移植瘤 Dosages: 每天3.75 mg/kg Administration: 瘤内注射 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	42 mg/mL (198.87 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Stattic SDF

分子量	211.19
化学式	C₈H₅NO₄S
CAS号	19983-44-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
We need to dissolve the compound for i.p. injection, could you give me some suggestions?
回答：
S7024 Stattic can be dissolved in 2% DMSO/PEG 300/dd H2O at 8 mg/mL as a clear solution.

研究领域

产品类型

定制您的化合物库

Stattic

客户使用Selleck生产的Stattic发表文献169篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Stattic SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

STAT Signaling Pathway Map

相关STAT产品